SEARCH · PubMed Health

Results for “Cancer Prevalence”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources

PubMed2004

Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.

Oral pseudomembranous candidiasis and mucositis were assessed in 39 patients receiving a total dose of 39-70 Gy radiotherapy for head and neck cancer. Mucositis was scored using the Radiation Therapy Oncology Group criteria, and oral candidiasis was diagnosed on the basis of clinical evaluation and quantitative laboratory findings. Radiation-induced mucositis was observed in 9/39 patients. Only 3/39 patients discontinued radiotherapy due to acute severe mucosal effects. Candidiasis (colony-forming units 35 to > or = 60/lesion) associated with mucositis was diagnosed in 30/39 patients: the most frequent aetiology of the infection was Candida albicans (n = 23), followed by Candida glabrata (n = 3), Candida krusei (n = 2), Candida tropicalis (n = 1) and Candida kefyr (n = 1). Patients with confirmed oral pseudomembranous candidiasis were treated with either fluconazole 200 mg/day or itraconazole 200 mg/day for 2 weeks. Clinical improvement and concomitant negative Candida cultures (mycologic cure) were the criteria determining a response to antifungal treatment. Etest revealed very low voriconazole MICs (0.004-0.125 microg/ml) for all isolates, and fluconazole resistance for eight C. albicans strains (MIC > 64 microg/ml) and for the C. krusei isolates (MIC > 32 microg/ml). The same strains showed itraconazole susceptibility dose dependence (MIC 0.5 microg/ml). Despite the itraconazole susceptible dose dependent MIC readings, all patients with oral pseudomembranous candidiasis caused by these strains responded to antifungal treatment with 200 mg/day itraconazole. Oral mycologic surveillance of patients undergoing radiotherapy for head and neck malignancies and susceptibility testing of isolates may be indicated in cases with mucositis-associated confirmed oral pseudomembranous candidiasis to ensure prompt administration of targeted antifungal treatment. On the basis of the low MIC values found, clinical evaluation of voriconazole is indicated for management of oral pseudomembranous candidiasis refractory to other azoles.

Adult↗

PubMed1993

Synchronous primary lung cancers: prevalence in surgical material and clinical implications.

BACKGROUND: The prevalence of synchronous primary lung neoplasms in surgical resection specimens was assessed. The associated clinical features and prognostic implications were investigated. METHODS: All surgical resections for lung cancer performed during seven years were reviewed. Synchronous tumours were defined by the presence of more than one tumour mass in the lung, by differences in histological subtype, by the presence of separate bronchial origins, or by differences in DNA stemlines. Clinical data were abstracted from case notes and information from the tumour registry. RESULTS: Just under 2% of all surgical specimens in the study period contained more than one primary carcinoma. The patients did not differ clinically from the general population of patients having surgery for lung cancer. The overall prognosis was poor (mean survival 27 months) but was significantly better for patients with synchronous squamous carcinomas (mean survival 49 months). CONCLUSION: Synchronous primary lung carcinomas are associated with a poor prognosis except in patients having tumours only of squamous histological type.

Adenocarcinoma↗

PubMed1988

Correlation between lung cancer prevalence and activities of aryl hydrocarbon hydroxylase and glutathione S-transferase in human lung tissues.

The activities of aryl hydrocarbon hydroxylase (AHH) and glutathione s-transferase (GST) were measured in the lung tissues of lung cancer patients and patients without lung cancer. The results indicate that after controlling for age, sex, smoking, living conditions, occupational exposure, and medication history, the ratio of AHH to GST (AHH/GST) in the lung tissues of cancer patients was significantly higher than that in noncancer patients. This difference might suggest a genetic difference in benzo[a]pyrene (BP) activations between the two groups of patients, but whether there is a casual relation between AHH/GST and lung cancer is still a question. AHH/GST was high in patients who smoked. It is conceivable that smoking might increase the rate of BP activation. There was a positive correlation between AHH activity and the amount the lung cancer patients smoked, but the AHH activity was not affected by smoking in noncancer patients. The AHH activity of lung cancer patients seems more sensitive to induction by polycyclic aromatic hydrocarbons than that of noncancer patients. However, this suggestion should be further verified.

Adult↗

PubMed1994

Follow-up of benign hypoechoic peripheral zone lesions of the prostate gland: US characteristics and cancer prevalence.

PURPOSE: To evaluate the role of biopsy-proved benign peripheral zone hypoechoic lesions of the prostate gland, ultrasonographic (US) characteristics at follow-up, prostate-specific antigen (PSA) levels, and digital rectal examination (DRE) in prediction of cancer risk. MATERIALS AND METHODS: Retrospective analysis was performed for 105 consecutive patients with 148 benign hypoechoic lesions discovered at transrectal US (TRUS) and diagnosed with US-guided needle biopsy. At least one repeat TRUS study was performed in each patient. RESULTS: Among the benign lesions, 72% changed at follow-up TRUS, either disappearing or becoming smaller, less hypoechoic, and more vague. Cancer developed in 13% of patients. In 93% of patients in whom cancer developed, the appearance changed in the peripheral zone at follow-up TRUS. In this patient population, the positive predictive value for development of cancer was 16% with a changing TRUS appearance, 19% with an abnormal DRE result, and 27% with an elevated level of PSA; only the latter was statistically significant. CONCLUSION: The PSA value, alone or in combination with a changing TRUS appearance, is the best indicator for development of cancer.

Adult↗

PubMed2007

Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale.

Comorbidity is defined as the presence of one or more diseases in addition to an index disease. In elderly people, the number and severity of comorbidity increase with age. We report the comorbidity data of 536 patients treated as in-patients: 231 elderly cancer patients (ECP), 172 younger cancer patients (YCP) and 133 elderly patients admitted for non-cancer reasons (EMP). Comorbidity was assessed with the cumulative illness rating scale geriatric version (CIRS-G). Data on number of affected organ systems (levels 1-4), number of affected organ systems with severe disease (levels 3-4), and sum score of levels per patient are reported. The number of comorbidities increases with age. A 76% of ECP, 51% of YCP, and 79% of EMP have severe comorbidity. Palliative treatment approach is not associated with higher levels of comorbidity in ECP. Vascular disorders were the most common comorbidity. The difficulty to rate haematological comorbidity in cancer patients is reflected. This is the first report on detailed results of assessment of comorbidity measured by CIRS-G in cancer patients. In addition, we provide a comparison to an elderly group of patients admitted for non-cancer reasons.

Age Factors↗

PubMed2004

Menetrier's disease in korea: report of two cases and review of cases in a gastric cancer prevalent region.

Menetrier's disease is a rare disease of the stomach generally described as hypertrophic gastropathy associated with hypoproteinemia. Gastric resection is still the most definitive treatment for the disease, but the appropriate extent of resection has not been determined. One of the major factors that would determine the extent of gastric resection in Menetrier's disease is its malignant potential. We present two recent cases of Menetrier's disease treated in our institution and review cases of the disease reported in Korea where the incidence of gastric cancer is one of the highest in the world.

Gastritis, Hypertrophic↗

PubMed2000

Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism.

UNLABELLED: The definitive treatment of hyperthyroidism in Europe is quite different from that in the United States. In Europe, the surgical approach is often preferred and considered safer than radioiodine treatment. European doctors usually prefer to surgically remove the thyroid and perform a pathologic examination of it. They consider it to be an essential diagnostic tool to identify possible diseases that might be associated with hyperthyroidism and even to detect the rare thyroid tumors that might be associated with thyroid hyperfunction. The aim of this study was to evaluate whether radioiodine therapy could be a risk factor for the misdiagnosis of thyroid cancer. METHODS: We performed a retrospective revision of data we collected from 6647 patients (1171 [17.5%] men, 5476 [82.5%] women), all of whom underwent 1311 therapy for hyperthyroidism from 1970 to 1997. Of the whole group, 6.5% were younger than 40 y, 33.5% were 40-60 y old, and 60% were older than 60 y. Moreover, 5061 (76%) patients had either an autonomously functioning node or a toxic multinodular goiter. The other 1586 (24%) patients had Graves' disease. RESULTS: After treatment, thyroid cancer was discovered in 10 (0.15%) patients, none of whom belonged to the group of patients with Graves' disease. Five of these patients were treated during a period from 1970 to 1980, when sonography was not routinely available. The incidence of thyroid cancer in the series of radioiodine-treated patients (150/100,000 over a 27-y period) was not significantly different from its incidence in the general population. The expected rate is 124.88 per 100,000 over a 27-y period. CONCLUSION: An accurate preliminary evaluation (clinical examination, sonography, and cytologic evaluation of fine-needle aspiration) is fundamental for a proper choice between radioiodine and surgical therapy.

Adult↗

PubMed1991

[Perineal pain and rectal cancer--prevalence in local recurrence].

Between 1983 and 1989, 85 patients with either carcinoma of the rectum or a recurrence of a previously diagnosed rectal tumour (47 women and 38 men aged 20 to 87 years) were treated in our pain clinic. In 50 patients, the reason for referral was perineal pain which had been present for one week to two years (median six months, 25%-percentile six weeks, 75%-percentile six months). In some patients this was considered to be due to scar tissue formation by the referring doctors. The pain was classified somatic, visceral and neuropathic in approximately equal numbers of patients, and about half of them described more than one type of pain. The other 35 patients were suffering from pain at other sites. In 40 out of 50 patients with perineal pain, local tumour recurrence was diagnosed. In 29 patients, pain symptoms began with a median of 5.5 months before the tumour recurrence was diagnosed. In a further seven patients, other types of tumour dissemination in the pelvis were considered to be the cause of the perineal pain. In only three patients no evidence of tumour was found in the pelvis. A non-neoplastic cause of perineal pain could be definitely confirmed in only one patient on post-mortem examination. 35 patients reported no perineal pain on admission, although in 19 cases a local cancer recurrence was found. 13 of these patients suffered from pain in the area of sensory innervation of the lumbosacral plexus. From 16 patients without a diagnosis of local recurrence, only four reported pain in this area.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

PubMed2005

Prevalence of cancer history prior to renal transplantation.

Recurrent and de novo cancers contribute to morbidity and mortality post-transplantation. However, data on cancer prevalence in waiting list patients are lacking. The purpose of this study was to determine the prevalence of malignancy in patients considered for renal transplantation. Records of 382 potential renal transplant recipients were reviewed for the presence of malignant tumours. In 38 patients 45 tumours were detected. Forty-two malignancies were histologically confirmed, in three patients the evaluation was ongoing. Fourteen tumours were diagnosed before and 31 after initiation of dialysis. Overall cancer prevalence was 9.9%. For patients in the waiting list, the mean time from diagnosis of the malignancy was 2.2 years. Twenty of 45 (44%) tumours were located in the urinary system. The majority of malignancies was treated with a curative intention. Thus, 68% of patients with malignancies were listed as 'transplantable' or 'temporarily not transplantable'. From the waiting list, 13% were removed , 8% died and 11% had their evaluation halted because of their malignancy. Four patients received a transplant while eight patients died or were removed permanently from the list prior to transplantation. Death or removal from the list was as frequently related to tumour progression as to other causes (four patients each). A substantial number of waiting list patients had a history of malignancy. Future strategies have to identify patients at risk to assure intensive monitoring for recurrence, selection of patients who do not benefit from deferred transplantation and consideration of specific immunosuppressive protocols.

Adult↗

PubMed2002